The FDA approved Sanofi’s Altuviiio in February 2023 as a once-weekly factor VIII replacement therapy for hemophilia A, offering sustained, near-normal factor activity levels. Positioned as a direct competitor to Roche’s Hemlibra, the drug aims to reduce injection frequency while providing high efficacy in clinical trials. Read the full story at MedCity News .

Sanofiвђ™s Fda Nod In Hemophilia Gives Patients More Convenience, Brings Roche New Competition Вђ“ — Mr Validity

The FDA approved Sanofi’s Altuviiio in February 2023 as a once-weekly factor VIII replacement therapy for hemophilia A, offering sustained, near-normal factor activity levels. Positioned as a direct competitor to Roche’s Hemlibra, the drug aims to reduce injection frequency while providing high efficacy in clinical trials. Read the full story at MedCity News .